Chemistry:Plinabulin
From HandWiki
| |
| Names | |
|---|---|
| IUPAC name
(3Z,6Z)-3-Benzylidene-6-{[5-(2-methyl-2-propanyl)-1H-imidazol-4-yl]methylene}-2,5-piperazinedione
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChemSpider | |
| KEGG | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C19H20N4O2 | |
| Molar mass | 336.395 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Tracking categories (test):
Plinabulin (provisional name BPI-2358, formerly NPI-2358) is a small molecule under development by BeyondSpring Pharmaceuticals, and is in a world-wide Phase 3 clinical trial for non-small cell lung cancer.[1] Plinabulin is being investigated for the reduction of chemotherapy-induced neutropenia[2] and for anti-cancer effects in combination with immune checkpoint inhibitors[3][4] and in KRAS mutated tumors.[5]
Plinabulin blocks the polymerization of tubulin in a unique manner, resulting in multi-factorial effects including an enhanced immune-oncology response,[6] activation of the JNK pathway[7] and disruption of the tumor blood supply.
References
- ↑ "Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion (DUBLIN-3)". https://clinicaltrials.gov/show/NCT02504489..
- ↑ Heist, R.S.; Aren, O.R.; Mita, A.C.; Polikoff, J.; Bazhenova, L.; Lloyd, G.K.; Mikrut, W.; Reich, W. et al. (2014). "Randomized Phase 2 Trial of Plinabulin (NPI-2358) Plus Docetaxel in Patients with Advanced Non-Small Lung Cancer (NSCLC)". J Clin Oncol 32:5s.
- ↑ "Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer". https://clinicaltrials.gov/show/NCT02846792.
- ↑ "Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)". https://clinicaltrials.gov/show/NCT02812667.
- ↑ Lloyd, G.K.; Du, L.; Lee, G.; Dalsing-Hernandez, J.; Kotlarczyk, K.; Gonzalez, K.; Nawrocki, S.; Carew, J. et al. (October 5–9, 2015). "Activity of Plinabulin in Tumor Models with Kras Mutations". Proceedings of the International Conference on Molecular Targets and Cancer Therapeutics. Boston MA.
- ↑ Lloyd, G.K.; Muller, Ph.; Kashyap, A.; Zippelius, A.; Huang, L. (January 7–9, 2016). "Plinabulin: Evidence for an Immune Mediated Mechanism of Action". Proceedings of the Meeting on the Function of Tumor Microenvironment in Cancer Progression. San Diego CA.
- ↑ Singh, A.V.; Bandi, M.; Raje, N.; Richardson, P.; Palladino, M.A.; Chauhan, D.; Anderson, K. (2011). "A Novel Vascular Disrupting Agent Plinabulin Triggers JNK-Mediated Apoptosis and Inhibits Angiogenesis in Multiple Myeloma Cells". Blood 117 (21): 5692–5700. doi:10.1182/blood-2010-12-323857. PMID 21454451.
 |  |
